Beck-NielsenSSBrock-JacobsenBGramJBrixenKJensenTK. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009;160(3):491-497.
2.
EndoIFukumotoSOzonoK, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811-816.
3.
RafaelsenSJohanssonSRæderHBjerknesR. Hereditary hypophosphatemia in Norway; a retrospective population-based study of genotypes, phenotypes and treatment complications. Eur J Endocrinol. 2016;174(2):125-136.
4.
CarpenterTOWhyteMPImelEA, et al. Burosumab therapy in children with X-linked hypophosphatemia. N Engl J Med. 2018;378(21):1987-1998.
5.
WhyteMPCarpenterTOGottesmanGS, et al. Efficacy and safety of burosumab in children aged 1-4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial. Lancet Diabetes Endocrinol. 2019;7(3):189-199.
